# The Effect of Serum Ferritin in irAE

> **NCT06702566** · NA · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 1500 (estimated)

## Conditions studied

- Immune-related Adverse Event
- Malignant Solid Tumors
- Acute Leukemia
- Serum Ferritin

## Interventions

- **DRUG:** PD-1 and PD-L1 inhibitor
- **DRUG:** Targeted drugs
- **DRUG:** chemotherapy drugs

## Key facts

- **NCT ID:** NCT06702566
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-04
- **Primary completion:** 2026-07-16
- **Final completion:** 2027-07-01
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06702566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06702566, "The Effect of Serum Ferritin in irAE". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06702566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*